Pyxis Oncology, Inc.
PYXS
Rank in Stocks
#19392
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company... Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
Share Price
$1.70
Last synced: 2026-11-09
Market Cap
$107.70M
Change (1 day)
2.41%
Change (1 year)
-62.80%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pyxis Oncology, Inc. (PYXS)
Category
Healthcare
EPS for Pyxis Oncology, Inc. (PYXS)
EPS as of September 2026 TTM: $-1.30
According to Pyxis Oncology, Inc.'s latest financial reports, its current EPS (TTM) is $-1.30. At the end of 2025 the company had an EPS of $-1.28, an increase over its 2024 EPS of $-1.32.
EPS history for Pyxis Oncology, Inc. from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.30 | 1.56% |
| 2025 | $-1.28 | -3.03% |
| 2024 | $-1.32 | -28.65% |
| 2023 | $-1.85 | -48.18% |
| 2022 | $-3.57 | 41.11% |
| 2021 | $-2.53 | 583.78% |
| 2020 | $-0.37 | 376.19% |
| 2019 | $-0.08 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,304.62% |
US
|
|
| $-7.07 | 443.85% |
US
|
|
| $-5.29 | 306.92% |
AU
|
|
| $12.88 | -1,090.78% |
BE
|
|
| $21.56 | -1,758.46% |
NL
|
Questions about Pyxis Oncology, Inc.'s earnings per share (EPS)
What is Pyxis Oncology, Inc.'s earnings per share (EPS)?
Pyxis Oncology, Inc.'s earnings per share (EPS) over the last twelve months is $-1.30, as of Sep 2026.
What was Pyxis Oncology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Pyxis Oncology, Inc.'s earnings per share (EPS) was $-1.28, compared with $-1.32 in 2024.
How has Pyxis Oncology, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pyxis Oncology, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.37) and lowest in 2022 ($-3.57).
How does Pyxis Oncology, Inc.'s earnings per share (EPS) compare with similar companies?
Pyxis Oncology, Inc.'s earnings per share (EPS) ($-1.30) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.